Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 22, 2026Clinical Transplantation

Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft‐Versus‐Host Disease: A Systematic Review and Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAhmed Farid GadelmawlaMenoufia UniversityMAMohamed A. AlsaiedMansoura UniversityMAMohanad A. AlkuwaitiImam Abdulrahman Bin Faisal University

Discussion

Loading...

Member takes

Implication

Systematic review evaluates efficacy and safety of belumosudil in chronic graft-versus-host disease, indicating significant potential benefits.

Key Points

  • This research evaluates the efficacy and safety of belumosudil in patients with chronic graft-versus-host disease (cGVHD).
  • Conducted a systematic review and meta-analysis of studies on belumosudil for cGVHD.
  • Searched multiple databases and assessed study quality using the MINORS tool.
  • Performed meta-analysis with an inverse variance random effect model.
  • Pooled overall response rate (ORR) at 12 months was 73%.
  • 58% of patients showed a reduction in corticosteroid use.
  • Overall survival at 12 months was 87% and at 24 months was 85%.
  • Any-grade adverse events occurred in 98% of patients, with common issues including diarrhea (22.1%) and headache (22.3%).

Cite This Study

Gadelmawla et al. (2026) studied this question.

synapsesocial.com/papers/6971bdad642b1836717e2589https://doi.org/10.1111/ctr.70458
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report2005 · 3,579 citations
  2. 2An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD2024 · 28 citations
  3. 3The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2021 · 107,295 citations
  4. 4Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation2006 · 522 citations
  5. 5How I treat steroid-refractory acute graft-versus-host disease2020 · 78 citations